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Abstract
Background: Nitrogen containing bisphosphonates such as zoledronic acid (ZA) are known to contain certain anti-
cancer properties. These have been investigated in the past in various cancers such as breast, prostate and colon.
ZA in particular has shown promising results in pre-clinical studies. We propose a multicentre double-blind
randomised controlled feasibility study to assess the recruitment and acceptability of ZA/placebo alongside
chemotherapy in malignant pleural mesothelioma (MPM).
Methods: Patients will be recruited for a 13-month period from October 2016 to November 2017. Eligible patients
will be identified via the regional mesothelioma multidisciplinary team meeting. Those who receive chemotherapy
will be randomised to receive either ZA or placebo alongside their chemotherapy. Those who decline chemotherapy
will be offered to join the trial on the non-randomised open-labelled arm of the trial. Patients will receive a maximum
of six cycles of ZA/placebo, at three-weekly cycles. All patients will be followed up for six months from randomisation.
Semi-structured interviews to gather data on acceptability of trial procedures, tolerability of ZA and other relevant
information will take place after the participants have completed their six cycles of treatment. For a better understanding
about non-participation in mesothelioma trials we also aim to interview those who decline to take part in the trial.
Discussion: The qualitative and quantitative data gathered in this feasibility trial will hopefully pave the way to designing
a robust full phase III trial to investigate the potential synergistic effect of ZA and current standard treatment for MPM,
cisplatin-pemetrexed combination chemotherapy.
Trial registration: ISRCTN Registry, ISRCTN45536692. Registered on 9 August 2016. EudraCT no. 2015–004433-26.
Keywords: Mesothelioma, Malignant pleural mesothelioma, Zoledronic acid, Mesothelin, PET-CT
Background
Malignant pleural mesothelioma (MPM) is an aggressive
and fatal tumour of the pleura that usually develops as a
consequence of previous asbestos exposure. Health and
Safety Executive data for 2012 show that mesothelioma
caused 2535 deaths in the UK (http://www.hse.gov.uk/Sta-
tistics/causdis/mesothelioma/mesothelioma.pdf). Median
survival without treatment for MPM is approximately
12 months; even with treatment the five-year survival rate
still remains low at 5% [1]. The currently accepted stand-
ard treatment of cisplatin-pemetrexed combination
chemotherapy only provides a modest survival benefit of
three months when compared to single agent cisplatin
alone, with only 40% of patients receiving chemotherapy
responding to the treatment [2]. Hence there is a clear
need to find novel treatments that work in MPM. As with
many other cancers, the limelight is currently on
immunotherapy and check-point blocking agents. Several
Phase I to III trials are currently investigating the effect of
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these novel therapies in MPM (NCT03063450, NCT025881
31, NCT02959463). To date, the best evidence with a good
survival benefit is shown with bevacizumab, an
anti-angiogenic targeting vascular endothelial growth factor
[3]. This treatment is not without its side effects and to date
has not been adopted by the National Institute for Health
and Care Excellence in the UK.
Bisphosphonates are a synthetic analogue of naturally oc-
curring pyrophosphate. Bisphosphonates are commonly
used in the treatment of osteoporosis and other bone disor-
ders, such as Paget’s disease, due to their action on inhibi-
ting osteoclast mediated bone resorption [4]. Nitrogen
containing bisphosphonates (n-bisphosphonates) have been
shown to inhibit various epithelial cancer cells in vitro, by
inhibiting the mevalonate pathway [5]. Potential
anti-tumour activity of bisphosphonates includes reduced
tumour angiogenesis, reduced tumour cell proliferation,
migration, invasion and adhesion, increased tumour cell
apoptosis and increased cytotoxicity of gamma-delta T cells,
which subsequently leads to reduced tumour vascularisa-
tion [6].
Several studies using n-bisphosphonates, particularly
zoledronic acid (ZA), have shown a survival benefit in
patients with breast cancer [7, 8]. In vivo studies on
mice inoculated with mesothelioma cells and treated
with bisphosphonates have shown a significant survival
advantage [9], supporting the direct anti-cancer properties
of bisphosphonates in mesothelioma. Similar results have
been seen in other in vivo studies of murine models inoc-
ulated with small-cell and non-small-cell lung cancer, both
showing a reduction in tumour burden and increased
survival in mice treated with n-bisphosphonates [10, 11].
ZA is known to be a potent nitrogen-containing bisphos-
phonate which has bone-independent anti-tumour activity.
In addition, when combined with certain chemotherapy
agents such as paclitaxel, etoposide, cisplatin and irinotecan
in lung cancers, it has an even greater synergistic effect in
induction of apoptosis in vitro [10].
As human studies investigating the synergistic effect
between ZA and chemotherapy do not exist, the
optimum timing of ZA in relation to chemotherapy is
still unknown. Murine models using subcutaneously
injected breast cancer cells have shown the greatest ef-
fect on increasing apoptosis; reducing proliferation and
neovascularisation was seen when the cytotoxic drug
was given 24 h after ZA [6].
A study by Jamil et al. [12] recently investigated the
role of single agent ZA in a small cohort of patients with
MPM who have either completed chemotherapy or were
too frail to receive chemotherapy. They demonstrated
some benefit with ZA, where there was a 37.5% rate of
clinical benefit (progression-free survival and stable
disease). Another study at our centre by Clive et al.,
looking at the role of ZA in malignant pleural effusions,
demonstrated two patients with MPM who showed a re-
duction in tumour bulk on radiology [13] after receiving
two doses of ZA intravenously.
A double-blind multicentre randomised controlled trial
(RCT) would be best placed to investigate the hypothesis
that treatment with the n-bisphosphonate ZA, in addition
to the standard chemotherapy (pemetrexed and cisplatin),
confers a survival benefit to patients with MPM compared
to chemotherapy alone. We propose a feasibility study
before undertaking a full study to capture the data needed
to inform a definitive phase III trial. In the Zol-A trial, we
are aiming to randomise 50 patients to receive either ZA
or placebo alongside chemotherapy. In our feasibility
study, a non-randomised third group will consist of
patients who are fit for chemotherapy but have declined
chemotherapy. These patients would be offered ZA in iso-
lation. Semi-structured interviews as a part of the trial will
help us to understand patient experiences, as well reasons
behind patients’ decisions to decline chemotherapy or
participating in the trial.
Methods
Feasibility outcomes
Our primary feasibility outcome is randomising 50 patients
over a 12-month period. In addition, we have a number of
secondary feasibility outcomes largely exploring the
acceptability of recruitment procedures, consent and ran-
domisation, data collection methods, acceptability of ZA in
MPM patients, and the optimal timing and location for ZA
administration. Qualitative analyses (QA) using semi-struc-
tured interviews are planned for patients who consent to
the trial (in the randomised and non-randomised arms)
and those who decline to participate in the trial, who agree
to participate in the interviews. Other feasibility outcomes
include: quantification of drop-out and data completeness
rates; estimates of outcome event rates, e.g. survival times;
measures of mean response and outcome variance (con-
tinuous variables such as quality of life) and confidence in-
tervals around estimates of proportions; and categorical
variables such as recruitment rates to use for calculating full
trial size and number of sites for a phase III trial.
Study overview
The trial is funded by the National Institute for Health
Research (NIHR), Research for Patient Benefit (RfPB)
funding stream. The trial protocol and related docu-
ments were reviewed by the Cambridge East Research
Ethics Committee (REC) and the necessary approvals
were granted in May 2016 (Reference no. 16/EE/0105).
The trial is registered with ISRCTN, trial registration
number 45536692. The trial is sponsored by North
Bristol NHS Trust.
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Study design
The Zol-A trial is a multicentre, double-blind RCT
assessing the feasibility of randomising 50 patients over
a 12-month period across three NHS sites in the South
West region of the UK. The lead centre is North Bristol
NHS Trust (NBT) while Bristol Haematology and
Oncology Centres at University Hospitals Bristol NHS
Foundation Trust and Royal United Hospitals NHS
Foundation Trust in Bath are the other two recruiting
centres.
Participant identification
Potential participants will be identified by the principal
investigators (PI) across the three sites, primarily from
the local lung cancer/mesothelioma multidisciplinary
team (MDT) meetings. The regional mesothelioma
MDT meeting is held at the lead centre NBT, which is
led by the chief investigator for the study. All new cases
of MPM from across the region (including the three
hospitals taking part in the trial) are discussed at this
meeting. Patients who meet the eligibility criteria will be
identified as potential participants.
Pre-screening, screening and recruitment
All patients with a new diagnosis of mesothelioma will
be pre-screened for the trial. Potential participants who
are eligible will be invited to take part in the trial. Pa-
tients will be given the patient information leaflet (PIL)
at the time of their diagnosis. Patients will be next
approached at the time of their first oncology clinic visit
for re-discussion of the trial; those who are happy to
take part will be invited to consent at this point. Doctor
consent will be obtained by those clinicians enrolled on
the delegation log.
Eligibility criteria
Inclusion criteria
If the participants meet all the following criteria they will
be eligible for the study:
 Histocytologically confirmed diagnosis of MPM
 World Health Organization (WHO) performance
status (PS) 0–1
 Eligible for first-line chemotherapy
 Ability to give informed consent
Exclusion criteria
If the participants meet any of the criteria below, they
will not be eligible for the study:
 Not fit for chemotherapy due to PS or other co-
morbidities
 Previous chemotherapy for MPM
 Intravenous bisphosphonate therapy in the
preceding three months
 Significant renal disease defined as an eGFR <
30 mL/min within the preceding four weeks
 Current hypocalcaemia receiving treatment or
evidence of hypocalcaemia within the preceding
six weeks
 Age < 18 years
 Severe untreated dental caries
 Concomitant participation in another drug trial for
MPM
 Allergy to 18-fluorodeoxyglucose used for PET scans
 Women of child-bearing potential (defined as fertile,
or following menarche and until becoming post-
menopausal unless permanently sterile).
Randomisation and blinding procedures
Patients will be allocated on a 1:1 basis to either the
intervention (ZA) or placebo. The allocation will be
blocked using varying block sizes and stratified accord-
ing to histological subtype (epithelioid or cytological ver-
sus non-epithelioid) using web-based software provided
by Sealed Envelope Ltd.
Participants and investigators will be blinded to the
treatment received. The ZA or placebo will be provided in
identically matched 100-mL 0.9% saline bags. The infusion
bag will contain the participant trial ID and randomisation
kit number. The allocation of treatment pertaining to the
relevant randomisation kit number will remain within the
pharmacies preparing the IMP/placebo.
Randomisation code breaking and emergency unblinding
The code should only be broken in circumstances when
knowledge of the IMP is required for treating the
patient. The chief investigator has the primary right to
break the blind if the circumstances warrant unblinding.
In a non-emergency situation where unblinding is
deemed necessary, the trial manager or the chief investi-
gator will review the necessity of unblinding. In an
emergency where unblinding is necessary, a 24-h rapid
code-breaking service is available via the unblinding
service provider based at Bristol Royal Infirmary (BRI)
clinical trials pharmacy. The BRI pharmacy will hold the
randomisation code list as well as restricted
password-protected access to the web-based electronic
randomisation services which would allow access to the
randomisation codes for each participant.
Trial interventions
Baseline assessment
A baseline assessment at the point of recruitment will
capture demographic data, participants’ current medica-
tions and investigations undergone for the diagnosis of
MPM. Participants will also have baseline bloods tests
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which include a full blood count, electrolyte levels (in-
cluding adjusted calcium level, magnesium and
phosphate), liver function tests and C-reactive protein
(CRP) level. A research-specific blood test, serum mesothe-
lin, will also be checked at the baseline assessment. Those
receiving ZA/placebo alongside chemotherapy will then be
randomised at the end of the baseline assessment. All
participants will receive calcium supplementation from
baseline assessment onwards, to prevent developing hypo-
calcaemia secondary to bisphosphonate therapy.
IMP/placebo schedule and administration
Patients in both the randomised and non-randomised
arms will receive up to a maximum of six cycles of ZA/
placebo, at three-weekly intervals. Participants who
stopped chemotherapy early, before the full six cycles,
due to toxicity or other reason will stop IMP/placebo at
the same time as their chemotherapy (Figs. 1 and 2).
ZA will be given in 100 mL of 0.9% saline over a
15-min period. The exact dose of the ZA will be
dependent on their most recent renal function (see
Table 1) which would be within the preceding
seven days.
Follow-up assessments
All participants will have a follow-up appointment be-
fore their next cycle of chemotherapy (See Additional
file 1). For patients in the randomised arm this often
corresponds to their pre-chemotherapy oncology assess-
ment visits. Data regarding adverse effects and other
Fig. 1 Trial flow chart
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symptoms will be captured at the follow-up appoint-
ment. If the blood tests identify any electrolyte distur-
bances, additional supplementation will be prescribed as
required.
A final follow-up appointment will take place at
six months from enrolment (Fig. 1).
Scans
All participants will have a baseline PET-CT scan before
receiving their first cycle of ZA/placebo and a further
CT and PET-CT scan after three cycles of treatment are
completed. A final CT scan will take place either after
the sixth cycle of treatment or at six months from enrol-
ment for those who do not complete the full course of
treatment.
Semi-structured interviews
As a feasibility study paving the way to a larger phase III
trial, we are keen to explore patient decisions behind
their chosen treatment option. Therefore, we would like
to interview a purposive maximum variation sample of
ten patients or up to data saturation, which will include
participants who are randomised, non-randomised and
those who decline participation in the trial altogether.
For participants who consent to the trial, this interview
will occur at the end of the trial. Those declining partici-
pation in the trial will be asked at the time whether they
would like to participate in the interview.
Statistical analysis
The analysis will be according to our feasibility objec-
tives detailed above. The information obtained from this
study will allow us to calculate numbers needed to treat
in the full trial. Assuming a 40% response rate for
chemotherapy alone, the difference in the number of pa-
tients with a disease response between the IMP group
and the placebo group will be used to calculate the sam-
ple size for the full trial. No formal interim analysis is
planned; the primary analysis will take place when
follow-up is complete for all recruited patients and the
database has been locked.
STUDY PERIOD
Enrolment Allocation Treatment Follow-up Close-out
TIMEPOINT** -t1 0 C1 C2 C3
Mid 
point C4 C5 C6
End of 
treatment
6-month 
ENROLMENT:
Eligibility screen X
Informed consent X
Randomisation X
INTERVENTIONS:
[Chemotherapy + 
ZA]
[Chemotherapy + 
placebo]
[Open labelled 
arm]
ASSESSMENTS:
Pet-CT scans 
X X
CT scans
X X X X
Qualitative 
interviews 
X
Data-analysis 
X
*Recommended content can be displayed using various schematic formats. See SPIRIT 2013 Explanation and Elaboration for examples from 
protocols.
**List specific timepoints in this row.
Fig. 2 SPIRIT figure
Table 1 Dose of ZA to be administered according to renal
function
Renal function Dose of ZA (mg)
eGFR ≥ 60 mL/min 4.0
eGFR 50–59 mL/min 3.5
eGFR 40–49 mL/min 3.3
eGFR 30–39 mL/min 3.0
eGFR < 30 mL/min 0.0
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Safety reporting
Standard definitions and clinical judgement will be
used when reporting any adverse events (AE) relating
to the trial. Given the nature of the disease and the
chemotherapy treatment patients are receiving, certain
adverse reactions are to be expected. The expected
AEs relating to the IMP and chemotherapy are as
listed below. All expected AE and serious adverse
event (SAE) data will be captured and reported as
appropriate.
Expected AEs relating to ZA:
– Flu-like symptoms
– Nausea
– Poor appetite
– Tiredness
– Sore eyes
– Redness and soreness around drip site
– Electrolyte disturbances (hypocalcaemia/
hypomagnesaemia/hypophosphataemia)
Expected AEs relating to chemotherapy:
– Flu-like symptoms
– Tiredness/lethargy
– Nausea and vomiting
– Gastrointestinal upset (diarrhoea)
– Skin reaction
– Peripheral neuropathy
– Pancytopaenia
– Neutropaenic sepsis
– Low folate levels
Expected SAEs relating to ZA and chemotherapy:
– Electrolyte disturbances requiring hospital admission
for replacement of electrolytes
– Neutropaenic sepsis requiring hospital admission
Data collection
All patients approached about the trial and given a PIL
will be captured on a screening log. Consent, baseline
information and blood results will be recorded on the
specific worksheets and subsequently entered onto an
electronic database, locally at the relevant sites. At each
pre-chemotherapy visit, the patients will have an assess-
ment covering any AEs/SAEs secondary to treatment
and have repeat blood tests performed. The results of
these and a quality-of-life measure will be documented
in the specific worksheets and subsequently entered on
to the database. Any CT and PET-CT scans will be
pseudo-anonymised to trial number and imported to the
local centre for assessment.
The trial team involved with conducting the trial at
the lead centre and the statistician will have access to
the final trial dataset once the database has been
locked down.
Trial management
A trial steering committee (TSC) comprising the key
members of the trial and a patient representative will
meet at the beginning, at six months and as necessary
thereafter until the trial has closed. An independent
data monitoring committee will meet at the start of
the trial and six months thereafter to review all safety
data and to advice the TSC whether to continue
recruiting to the trial.
Discussion
The Zol-A trial is studying a cohort of patients with an in-
curable cancer who have limited treatment options. The
standard treatment with chemotherapy only has a small ef-
fect on prolongation of life hence the need for identifying
new treatment options. The objective of this feasibility trial
is to gather data from a small number of patients with a
diagnosis of MPM and an even smaller number of patients
who would be eligible for first-line treatment options.
Several MPM treatment trials have terminated early due to
poor recruitment (NCT00597116, NCT00003508). It is be-
coming apparent that even those who would be eligible for
chemotherapy are declining the standard treatment due to
the poor effectiveness and the toxic side effects associated
with the treatment [14]. The semi-structured interviews
aim to capture all patient groups involved in the trial to
identify reasons behind why patients opt in and out of re-
search trials and chemotherapy treatment. Furthermore, we
are looking at their experiences of receiving ZA alongside
standard treatment of chemotherapy and the acceptance of
this combination.
To obtain efficacy data for the ZA/chemotherapy
combination, the number needed to treat is likely to be
significantly large. Therefore, considering the outcome
of a number of prematurely terminated trials and the
large numbers required to obtain any efficacy data with
ZA, we embarked on the feasibility trial first. This trial
will provide us with radiological information on tumour
response after treatment and progression-free survival
data which will be used to inform the power calculation
when designing the phase III trial. With a disease such
as MPM where survival is poor, it is essential to quantify
drop-out rates and data completeness rates before de-
signing a full trial and this feasibility trial will assist with
estimating these numbers.
The trial design is not without fault. The number of 50
randomised patients in 12 months across three sites is
ambitious. The trial will recruit for 13 months in total but
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for the purpose of our primary feasibility outcome we will
look at a 12 consecutive-month period (Additional file 2).
Trial status
The trial opened to recruitment simultaneously across
the three sites in October 2016 and will close to recruit-
ment in November 2017. The study will close when all
recruited patients have completed their six-month
follow-up appointment.
Protocol version and date
The protocol published here is version 5.0 dated 19 Sep-
tember 2017. Table 2 contains a list of amendments to
date.
Additional files
Additional file 1: Study visit schedule. (DOCX 160 kb)
Additional file 2: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*. (DOC 122 kb)
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Table 2 Amendments to date
List of amendments Summary of change
SA01
14/09/2016
• Personnel randomising to the trial has changed from pharmacy to research members as the randomisation software
allows randomisation while protecting the blind
• Minor change to inclusion criteria – removed ‘modified RECIST’ from measurable disease section
SA02
25/01/2017
• Change to eligibility criteria – removed ‘measurable disease on CT (tumour thickness > 5 mm)’
• Dr. Steve Walker added as sub-investigator
• Radiological data collection is further explained in section 5.13
• Plan of analysis (Section 6.1) details how the radiological information will be used to calculate the sample size for the full study
SA03
26/04/2017
• Addition of Patient appointment schedule v1.0 22/03/17
SA04
08/09/2017
• Request to interview patients who decline participation in the trial
• Clarify number of patients for semi-structured interview (up to data saturation rather than the previously stated 10)
NSA01
20/09/2017
• Extend recruitment period by 1 month, to November 2017
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